Estrogen Receptor Alpha Controls a Gene Network in Luminal-like Breast Cancer Cells Comprising Multiple Transcription Factors and MicroRNAs
Overview
Authors
Affiliations
Luminal-like breast tumor cells express estrogen receptor alpha (ERalpha), a member of the nuclear receptor family of ligand-activated transcription factors that controls their proliferation, survival, and functional status. To identify the molecular determinants of this hormone-responsive tumor phenotype, a comprehensive genome-wide analysis was performed in estrogen stimulated MCF-7 and ZR-75.1 cells by integrating time-course mRNA expression profiling with global mapping of genomic ERalpha binding sites by chromatin immunoprecipitation coupled to massively parallel sequencing, microRNA expression profiling, and in silico analysis of transcription units and receptor binding regions identified. All 1270 genes that were found to respond to 17beta-estradiol in both cell lines cluster in 33 highly concordant groups, each of which showed defined kinetics of RNA changes. This hormone-responsive gene set includes several direct targets of ERalpha and is organized in a gene regulation cascade, stemming from ligand-activated receptor and reaching a large number of downstream targets via AP-2gamma, B-cell activating transcription factor, E2F1 and 2, E74-like factor 3, GTF2IRD1, hairy and enhancer of split homologue-1, MYB, SMAD3, RARalpha, and RXRalpha transcription factors. MicroRNAs are also integral components of this gene regulation network because miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol along with other microRNAs that can target a significant number of transcripts belonging to one or more estrogen-responsive gene clusters.
Arumalla K, Haince J, Bux R, Huang G, Tappia P, Ramjiawan B Int J Mol Sci. 2024; 25(23).
PMID: 39684741 PMC: 11641454. DOI: 10.3390/ijms252313029.
Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy.
Jin Y, Lee Y ChemMedChem. 2024; 19(23):e202400267.
PMID: 39136599 PMC: 11617661. DOI: 10.1002/cmdc.202400267.
Ortiz J, Lewis S, Ciccone M, Chatterjee D, Henry S, Siepel A J Mammary Gland Biol Neoplasia. 2024; 29(1):3.
PMID: 38289401 PMC: 10827859. DOI: 10.1007/s10911-023-09553-x.
Genome-wide DNA methylation changes upon DOT1L inhibition in hormone-responsive breast cancer cells.
Giurato G, Terenzi I, Chiuso F, Salvati A, Rizzo F, Tarallo R Front Cell Dev Biol. 2023; 11:1308025.
PMID: 38099289 PMC: 10720356. DOI: 10.3389/fcell.2023.1308025.
Chromatin Organization and Transcriptional Programming of Breast Cancer Cell Identity.
Bobbitt J, Seachrist D, Keri R Endocrinology. 2023; 164(8).
PMID: 37394919 PMC: 10370366. DOI: 10.1210/endocr/bqad100.